Thomas Gad (chairman) is Founder, President and Head of Business Development and Strategy. Thomas Gad founded YmAbs in April 2014 inspired by his daughter going through 6 years of treatment overcoming high-risk neuroblastoma receiving break-through cancer immunotherapy at Memorial Sloan Kettering Cancer Center (MSK), and secured executive management and seed capital for inception of the Company. Thomas Gad has more than 12 years industry experience from the pharmaceutical industry, including business development, senior management, financing and licensing negotiations. Thomas Gad has a Bachelor of Science in Business Administration from Pepperdine University, California, USA.
Gregory Raskin, MD is Vice President, Technology Development at Memorial Sloan Kettering Cancer Center (MSK), where he leads technology transfer, commercialization, and business development at the world's oldest and largest private cancer center. Prior to joining MSK in 2012, Dr. Raskin was a Vice President at Alliance Bernstein LP, where he led healthcare and life sciences investing for the firm's $200 million venture capital fund. Dr. Raskin's previous experience includes serving as a biotech analyst at Baker Brothers Investments and as a management consultant at McKinsey & Company, where he worked mainly with pharmaceutical and biotech companies. Dr. Raskin received both his bachelor's degree in molecular biophysics and biochemistry and his medical degree from Yale University. Dr. Raskin also was a resident physician in the internal medicine department of New York University Medical Center.
Claus Moller, MD, PhD serves as Chief Executive Officer of the Company. Claus Moller is the Founder of Azanta A/S and was the Chief Executive Officer of Azanta from 2009 to 2015. In addition, Claus Moller has extensive experience in the pharmaceutical and biotechnology industries and was a co-founder of one of the largest European biotech companies, Genmab, in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Previous positions include Executive Vice President and Chief Medical and Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Claus Moller received his M.D. and Ph.D. degrees from the University of Copenhagen.
Johan Wedell-Wedellsborg is Owner and Chairman of the Board of Weco Group, which he took over in 2001. Weco Group is primarily a Ship Owning Company, which operates within the product tanker segment, multi-purpose vessels, RORO line and handy size bulk carriers. The shipping part of Weco Group records annual revenue of approximately $200 million. Besides shipping, Weco Group also is involved in realty investments, financial services, art and biotech. Johan Wedell-Wedellsborg is member of the Board of Directors for Cirque France SAS and Joe & The Juice A/S, and he is educated within shipping in Hamburg, Germany and has also worked out of London in the United Kingdom and Houston, Texas.
Bo Kruse serves as Chief Financial Officer, Treasurer and Secretary of the Company. Bo Kruse has broad international finance experience, including knowledge of capital markets, accounting and other financing activities. Prior to joining the Company, Bo Kruse was the Chief Financial Officer of the Danish biotech company Azanta from 2009 to 2015. Further, Bo Kruse served as Genmab’s Vice President and Chief Financial Officer from 2005 to 2008 and in a number of other finance positions, including Vice President and Chief Accounting Officer, from 2000 to 2005. During his eight year tenure at Genmab, Bo Kruse was directly involved in several financing rounds, including Genmab’s initial public offering. Bo Kruse has a Master and Bachelors of Science in Commerce from the Copenhagen Business School.
Michael Buschle, PhD, serves as a consultant and venture partner of HBM Partners AG. From April 2006 to December 2016, Dr. Buschle held various positions within Glenmark Pharmaceuticals Ltd., including President Biologics and Chief Scientific Officer. Prior to Glenmark, Dr. Buschle held various positions at Intercell AG, of which he was one of the Co- Founders, including Chief Scientific Officer. Prior to forming Intercell, Dr. Buschle held a position at Boehringer Ingelheim GmbH, Vienna. Dr. Buschle’s scientific career has included work at the Royal Free Hospital School of Medicine, London, United Kingdom, the St. Jude Children’s Research Hospital, Memphis, Tennessee and at the Boehringer Ingelheim-owned Institute of Molecular Pathology, Vienna, Austria. Dr. Buschle holds a PhD from the University of London.
Ashutosh Tyagi, MD, serves as a Partner and Co-Portfolio Manager of health care funds at Scopia Capital Management LP, an institutional alternative asset management firm with over $6 billion of assets under management. He joined Scopia Capital Management in 2010 and prior to this, he worked at Lombard Odier, Morgan Stanley, and Citigroup. Dr. Tyagi holds a BA in Asian Studies from the University of Michigan, an MBA from the University of Michigan Business School and an MD from the University of Michigan School of Medicine
James I. Healy, MD, PhD has been a general partner at Sofinnova Ventures Inc. since 2000. Prior to this, Dr. Healy held various positions at Bayer Healthcare Pharmaceuticals, Sanderling Ventures, and ISTA Pharmaceuticals, Inc. Dr. Healy is currently on the board of directors of Ascendis Pharma A/S, Coherus BioSciences, Inc., Edge Therapeutics, Inc., Obseva SA, Natera, Inc., NuCana plc and several private companies. Previously, Dr. Healy served as a board member of Amarin Corporation plc, Anthera Pharmaceuticals, Auris Medical Holding AG, Durata Therapeutics, Inc., Hyperion Therapeutics, Inc., InterMune, Inc., KaloBios Pharmaceuticals, Inc., Movetis NV and a number of private companies. Dr. Healy holds a BA in Molecular Biology and a BA Scandinavian Studies from the University of California at Berkeley, and an MD and PhD in Immunology from Stanford University School of Medicine.
David N. Gill, is formerly Chief Financial Officer of EndoChoice Holdings, Inc., a publicly traded medical device company, and he also served as EndoChoice’s President and Chief Operating Officer from March 2016 to November 2016. He served as the Chief Financial Officer of INC Research Holdings Inc., from February 2011 to August 2013, and served as a board member and audit committee chairman of INC Research from 2007 to 2010. Prior to this, Mr. Gill was the Chief Financial Officer of TransEnterix, Inc., Chief Financial Officer and Treasurer of NxStage Medical, Inc., a publicly traded dialysis equipment company as well as SVP and Chief Financial Officer of CTI Molecular Imaging, Inc. Since February 2015, he has served as a director and chair of the audit committee of Histogenics Inc. Mr. Gill also currently serves as a director and chair of the audit committee of Melinta Therapeutics, Inc. From 2006 to 2011, he served on several public and private company boards of directors. Mr. Gill holds a BS, cum laude, in Accountancy from Wake Forest University and an MBA, with honors, from Emory University. Mr. Gill was formerly a certified public accountant.